VistaGen Therapeutics
VTGN
104 hedge funds and large institutions have $360M invested in VistaGen Therapeutics in 2021 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 35 increasing their positions, 29 reducing their positions, and 12 closing their positions.
50% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 12
21% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 29
3% more funds holding
Funds holding: 101 → 104 (+3)
0.12% more ownership
Funds ownership: 2.15% → 2.27% (+0.12%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
7% less capital invested
Capital invested by funds: $387M → $360M (-$26.5M)
93% less call options, than puts
Call options by funds: $50K | Put options by funds: $704K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$13.9M |
| 2 |
CC
Commodore Capital
New York
|
+$5.19M |
| 3 |
Goldman Sachs
New York
|
+$3.01M |
| 4 |
EGI
EAM Global Investors
Solana Beach,
California
|
+$1.84M |
| 5 |
Two Sigma Advisers
New York
|
+$1.39M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$4.51M |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
-$915K |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$741K |
| 4 |
SB
Samsara BioCapital
Palo Alto,
California
|
-$707K |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
-$554K |
VTGN Hedge Fund Activity: Q3 2021 in Review
104 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in VistaGen Therapeutics (VTGN) for Q3 2021, worth a combined $360M — down 6.8% from $387M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new VTGN positions and 12 closed out — a net gain of 6 holders — while 35 added to existing stakes and 29 trimmed.
The largest buyer was State Street, adding an estimated $13.9M. The largest seller was OrbiMed, cutting an estimated $4.51M.
- 104 institutional investors held VistaGen Therapeutics (VTGN) as of Q3 2021, up from 101 in Q2 2021.
- Funds reported $360M of VistaGen Therapeutics stock for Q3 2021, down 6.8% quarter-over-quarter.
- 18 funds opened new VistaGen Therapeutics positions in Q3 2021 and 12 closed out, a net change of +6 holders.
- The largest VistaGen Therapeutics buyer in Q3 2021 was State Street, an estimated $13.9M added.
- The largest VistaGen Therapeutics seller in Q3 2021 was OrbiMed, an estimated $4.51M sold.
Based on aggregated 13F filings for Q3 2021.